Doris Benbrook to Adult
This is a "connection" page, showing publications Doris Benbrook has written about Adult.
Connection Strength
0.290
-
Correlation of clinical data with fallopian tube specimen immune cells and tissue culture capacity. Tissue Cell. 2018 Jun; 52:57-64.
Score: 0.064
-
The pro-inflammatory effect of obesity on high grade serous ovarian cancer. Gynecol Oncol. 2016 10; 143(1):40-45.
Score: 0.057
-
A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Nov; 127(2):356-61.
Score: 0.043
-
A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecol Oncol. 2007 Sep; 106(3):596-603.
Score: 0.030
-
Cognitive Performance in Relation to Systemic and Brain Iron at Perimenopause. Nutrients. 2025 Feb 20; 17(5).
Score: 0.026
-
Retinoids and steroids regulate menstrual phase histological features in human endometrial organotypic cultures. Fertil Steril. 2002 Sep; 78(3):596-602.
Score: 0.022
-
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 05; 145(2):291-297.
Score: 0.015
-
A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014 Oct; 135(1):38-43.
Score: 0.012
-
The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer. Gynecol Oncol. 2013 Aug; 130(2):377-82.
Score: 0.011
-
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol. 2011 Jun 01; 121(3):455-61.
Score: 0.010